Clinical Trials Logo

Pyelonephritis clinical trials

View clinical trials related to Pyelonephritis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06299215 Not yet recruiting - Pyelonephritis Clinical Trials

Factors and Prognosis of Obstructive Pyelonephritis Patients

PYELO-OBS
Start date: April 15, 2024
Phase:
Study type: Observational

Acute obstructive pyelonephritis is a condition with a high risk of complications and may require admission to the intensive care unit. Most of the available data on this condition comes from small, retrospective, single-centre series. To date, no large-scale study has examined the factors associated with the prognosis of patients admitted to intensive care for acute obstructive pyelonephritis. The aim of this study is to describe the population and prognosis of patients admitted to the intensive care unit for the management of acute obstructive pyelonephritis, and to identify factors associated with a poor prognosis in these patients.

NCT ID: NCT06144060 Not yet recruiting - Clinical trials for Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

Start date: December 2023
Phase: Phase 2
Study type: Interventional

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS -8427 in patients with complicated urinary tract infection, including acute pyelonephritis.

NCT ID: NCT06128213 Not yet recruiting - Clinical trials for Urinary Tract Infections

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

Start date: March 31, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical study is to test NRX101 in participants with complicated urinary tract infections including pyelonephritis. The main questions it aims to answer are: - Does NRX101 help participants resolve UTIs? - Is NRX101 safe for participants with UTIs? Participants will be seen in a doctor's office approximately 6 times to: - Answer a short 10 item questionnaire. - Review of side effects - Urine tests - Blood draw (about 10 ml or 2 teaspoons) - Review of medications - Review any signs or symptoms of UTI - Vital signs and weight (including blood pressure, heart rate, respiratory rate, and temperature) - Review of medical history This is an open-label study of NRX101, which means both you and your doctor know what drug you are taking. After the study is completed, researchers will look at the data to see if NRX101 helps participants with complicated UTI's.

NCT ID: NCT05204368 Not yet recruiting - Clinical trials for Complicated Urinary Tract Infection Including Acute Pyelonephritis

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Start date: March 30, 2023
Phase: Phase 3
Study type: Interventional

This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis.

NCT ID: NCT05060419 Not yet recruiting - Clinical trials for Acute Pyelonephritis

Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

Start date: October 8, 2021
Phase: Phase 2
Study type: Interventional

Phase 2, randomised, double-blind,double-dummy study in hospitalised adults with complicated urinary tract infection (cUTI), including acute pyelonephritis.Treatment duration for each cohort was 7 to 14 days. Patients were not permitted to switch to oral therapy.

NCT ID: NCT03630081 Not yet recruiting - Clinical trials for Acute Pyelonephritis

Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Start date: January 2024
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-TAZ vs. meropenem in the treatment of hospitalized adults with cUTI or AP.